29 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
18
Ending by 2030
Dec 2026
Next term end
22
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2028 · High confidence
Also notable
Ends Mar 2027 · High confidence
Also notable
Ends Jul 2031 · High confidence
Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition
US 9,725,694
Cited by 62 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Placental Stem Cell Populations
US 8,202,703
Cited by 76 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Methods of Generating Natural Killer Cells
US 8,926,964
Cited by 49 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Treatment of Pain Using Placental Stem Cells (US 9,040,035) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 1 fee due Dec 25, 2026The maintenance fee for Enhanced Placental Stem Cells and Uses Thereof (US 10,329,529) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Jan 11, 2027The maintenance fee for Use of Placental Stem Cells in Treatment of Acute Kidney Injury (US 11,696,930) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Treatment of Inflammatory Diseases Using Placental Stem Cells (US 11,723,930) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 1, 2027The maintenance fee for Treatment of Bone-Related Cancers Using Placental Stem Cells (US 9,121,007) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 3 fees due Jun 1 to 22, 2027 · next Jun 1
- 3 fees due Aug 9 to 18, 2027 · next Aug 9
Recent changes
- 7 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 22 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Placental Stem Cell Populations | 3 in force | to Mar 2027 |
| Enhanced Placental Stem Cells and Uses Thereof | 2 in force | to Mar 2034 |
| Treatment of Pain Using Placental Stem Cells | 2 in force | to May 2032 |
| Treatment of Inflammatory Diseases Using Placental Stem Cells | 2 in force | to Dec 2029 |
| Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition | 2 in force | to Oct 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,078,898 | Placental Stem Cell Populations In force · High confidence | In force | High confidence | |
| US 10,383,897 | Placental Stem Cell Populations In force · High confidence | In force | High confidence | |
| US 10,590,381 | Composition for Collecting and Preserving Placental Stem Cells and Methods of Using the Composition In force · High confidence | In force | High confidence | |
| US 8,202,703 | Placental Stem Cell Populations In force · High confidence | In force | High confidence | |
| US 9,364,585 | Methods for Collecting and Using Placenta Cord Blood Stem Cells In force · High confidence | In force | High confidence | |
| US 10,548,926 | Methods for Collecting and Using Placenta Cord Blood Stem Cells In force · High confidence | In force | High confidence | |
| US 8,071,376 | Production of Oligodendrocytes from Placenta-Derived Stem Cells In force · High confidence | In force | High confidence | |
| US 8,877,180 | Human Placental Collagen Compositions, and Methods of Making and Using the Same In force · Low confidence | In force | Low confidence | |
| US 8,916,146 | Treatment of Inflammatory Diseases Using Placental Stem Cells In force · High confidence | In force | High confidence | |
| US 10,494,607 | CD34+,CD45- Placental Stem Cell-Enriched Cell Populations In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 23 patents ended · 12 applications pending · 12 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.